Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
An insulin pen and blood glucose meter on a kitchen countertop

Aug 4, 2026

I’m using not-FDA-approved software to manage my diabetes. I’ve never felt better

A patient with type 1 diabetes has turned to open-source software for managing their condition, reporting significant improvements in glucose control compared to traditional FDA-approved systems.After over three decades of managing type 1 diabetes with FDA-regulated insulin pumps and sensors, the patient experienced a decline in glucose control. Upon their physician's recommendation, they began using an open-source software solution that optimizes insulin delivery more effectively than existing
Flat design of a bispecific antibody-drug conjugate

Aug 4, 2026

Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact

Pathos AI has expanded its therapeutic pipeline through a significant acquisition from Alphamab Oncology and a collaboration with AstraZeneca, reflecting its commitment to leveraging AI in drug development.The New York-based biotechnology firm has agreed to pay $125 million for the bispecific antibody-drug conjugate (ADC) JSKN016, which targets TROP2 and HER3. This ADC is already in phase 3 trials, demonstrating its advanced stage in development. Pathos AI utilized its AI-driven decision platfor
A minimalist illustration of a sleeping figure with sleep cycle waves above.

Aug 4, 2026

AI Identifies Previously Unrecognized Health Insights in Routine Sleep Studies

A new AI model has been developed that analyzes data from routine sleep studies to identify long-term health risks, revealing previously unrecognized insights into patient health. This innovative approach, led by a multidisciplinary team including Cleveland Clinic researchers, demonstrates that standard sleep tests can provide richer physiological data than typically utilized in clinical practice.The research, published in Nature Communications, highlights the model's ability to categorize patie
Press release cover image

Aug 4, 2026

Press release

Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic

Pathos assumes responsibility for early clinical development of AZD4241, utilizing its AI-driven Foundry platform to drive patient stratification and trial design.NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a collaboration and co-exclusive licensing agreement with AstraZeneca. Under this agreement, the companies will advance AZD4241, a preclinical investigational therapy for patients with estroge
Press release cover image

Aug 4, 2026

Press release

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC

NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”), a wholly-owned subsidiary of Alphamab Oncology (Stock Code: 9966.HK), on JSKN016, a first-in-class (FIC) TROP2/HER3 bispecific antibody-drug conjugate (ADC) independently developed by Alphamab.Pursuant to the licensing agreement, Alphamab granted Pathos an exclusive l
Press release cover image

Aug 4, 2026

Press release

CORRECTING and REPLACING Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline

Futures Lab identified 45+ therapeutic opportunities on a $33,000 budget, expands to 13 university partners with 100% retention, and uncovers assets representing more than $500 million in prior industry investment.RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Please replace the release dated July 31, 2026, with the following corrected version due to multiple minor revisions.The updated release reads: LŌKAHI THERAPEUTICS™ AI² FUTURES LAB™ CHANGES HOW BIOPHARMA BUILDS A PIPELINEFutures
A clinical trial vial and syringe on a lab bench in a clinical setting.

Aug 3, 2026

Straive Named a Leader in AIM Research’s 2026 PeMa Quadrant for Life Sciences and Healthcare AI Services

Straive has achieved recognition as a Leader in AIM Research’s 2026 Penetration Maturity (PeMa) Quadrant for AI services in the life sciences and healthcare sectors.This accolade highlights Straive’s comprehensive capabilities in various critical areas, including clinical development, regulatory affairs, and pharmacovigilance. AIM Research, known for its focus on AI and data science, aims to assist enterprise buyers in evaluating technology and service providers through its PeMa Quadrants.Straiv
Press release cover image

Aug 3, 2026

Press release

Nuclio Launches the First Business Media and Professional Networking Platform Dedicated to the Nuclear Medicine Economy

Nuclio News and MyNuclio combine industry journalism, professional networking and commercial intelligence to serve one of healthcare’s fastest-growing sectorsAs billions of dollars flowinto radiopharmaceuticals, medical isotopes and precision oncology, a new mediacompany is betting that one of healthcare's fastest-growing industries needsmore than another publication—it needs its own commercial ecosystem.Today, Nuclio announced thelaunch of Nuclio News, adigital business publication covering the
A tissue sample on a microscope slide in a clinical lab setting.

Aug 3, 2026

NYU Langone, Dana-Farber join forces to advance oncology decision support

NYU Langone Health and Dana-Farber Cancer Institute are collaborating to develop Solavia, an innovative oncology analytics platform aimed at enhancing decision-making in cancer care.This new platform seeks to standardize care pathways and improve governance, digital pathways, and implementation science in oncology. Launched on June 30, Solavia integrates seamlessly into existing workflows, allowing healthcare teams to access vital oncology data, including evidence and treatment options, thereby
A minimalist illustration of a pill bottle against a dark background, symbolizing prescription safety.

Aug 3, 2026

AI alone cannot solve Rx translation

Recent discussions highlight the need for caution in employing AI for translating prescription labels, emphasizing that language access should prioritize patient safety over mere compliance.Health systems are increasingly adopting generative AI for various applications, yet the translation of prescription labels remains a critical area requiring careful consideration. Sharon Blank, CEO of RxTran, points out that the main challenge is not the technology itself but the perception of language acces
Press release cover image

Aug 3, 2026

Press release

CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that it has entered into a strategic transaction to increase its equity stake in Sarborg Limited (“Sarborg”), an agentic AI signature intelligence business operating across multiple industrial sectors, to 22.7% through the issuance of pre-funded warrants to purchase up to 12,131,770 shares of the Company’s common stock, subject to shareholder appr
A minimalist representation of a peptide structure and AI model in flat design.

Aug 3, 2026

Receptor.AI and Sethera Plan to Create Closed-Loop Discovery and Optimization Workflow for Difficult Therapeutic Targets

Receptor.AI and Sethera are collaborating to develop an innovative closed-loop drug discovery workflow aimed at addressing challenging therapeutic targets.The partnership will leverage Sethera's advanced platform, which enables the creation and experimental screening of diverse polymacrocyclic peptide libraries. This approach allows for the generation of unique peptide architectures, moving beyond traditional design methods that rely on fixed structural motifs. Receptor.AI will complement this b